Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
NCT04762875 · Ensoma · PHASE2 · terminated · last registry update 2024-11-06 · Childhood acute lymphoblastic leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This study was voluntarily terminated due to a business decision not to proceed and not due to any safety issue” | – | Registry record, Ensoma |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CXCR4 in childhood acute lymphoblastic leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision